This trial assessed the efficacy of a sequential treatment approach involving TACE and stereotactic body radiotherapy, culminating in avelumab administration—an anti‐PD‐L1 therapy—for locally advanced, unresectable HCC. The gene discussed is CD274; the disease is hepatocellular carcinoma.